How do you help your patients when…?
Up to 50% of CSU patients have an inadequate response to H1-antihistamines at licensed doses1,2
Beyond Xolair®, there are no other licensed treatment options for inadequately controlled CSU patients1
Until now, there has been no standard of care for these inadequately controlled CSU patients1
*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only
†Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients
‡Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.
References: 1. Maurer M et al. Allergy 2011;66:317-330 2. Weller K, et al. J Eur Acad Dermatol Venereol 2013;27:43–50. 3. Maurer M, et al. N Engl J Med 2013;368:924-935. 4. Zuberbier T et al. Allergy 2014; 69:868-887
